CRISPR Therapeutics (CRSP) Revenue & Revenue Breakdown
CRISPR Therapeutics Revenue Highlights
Latest Revenue (Y)
$370.00M
Latest Revenue (Q)
$517.00K
Main Segment (Y)
Collaboration Revenue
CRISPR Therapeutics Revenue by Period
CRISPR Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $370.00M | 84762.39% |
| 2022-12-31 | $436.00K | -99.95% |
| 2021-12-31 | $913.08M | 168054.88% |
| 2020-12-31 | $543.00K | -99.81% |
| 2019-12-31 | $289.59M | 9169.85% |
| 2018-12-31 | $3.12M | -92.38% |
| 2017-12-31 | $41.00M | 693.90% |
| 2016-12-31 | $5.16M | 1990.69% |
| 2015-12-31 | $247.00K | 100.00% |
| 2014-12-31 | - | - |
CRISPR Therapeutics generated $370.00M in revenue during NA 2023, up 84762.39% compared to the previous quarter, and up 11843.79% compared to the same period a year ago.
CRISPR Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $517.00K | 2.58% |
| 2024-03-31 | $504.00K | -99.75% |
| 2023-12-31 | $200.00M | 100.00% |
| 2023-09-30 | - | -100.00% |
| 2023-06-30 | $70.00M | -30.00% |
| 2023-03-31 | $100.00M | 1666566.67% |
| 2022-12-31 | $6.00K | -93.62% |
| 2022-09-30 | $94.00K | -40.51% |
| 2022-06-30 | $158.00K | -11.24% |
| 2022-03-31 | $178.00K | -98.56% |
| 2021-12-31 | $12.35M | 3653.19% |
| 2021-09-30 | $329.00K | -99.96% |
| 2021-06-30 | $900.20M | 445544.55% |
| 2021-03-31 | $202.00K | 4.12% |
| 2020-12-31 | $194.00K | 31.08% |
| 2020-09-30 | $148.00K | 236.36% |
| 2020-06-30 | $44.00K | -71.97% |
| 2020-03-31 | $157.00K | -99.80% |
| 2019-12-31 | $77.02M | -63.66% |
| 2019-09-30 | $211.93M | 66544.03% |
| 2019-06-30 | $318.00K | -3.05% |
| 2019-03-31 | $328.00K | 185.22% |
| 2018-12-31 | $115.00K | -79.57% |
| 2018-09-30 | $563.00K | -48.25% |
| 2018-06-30 | $1.09M | -19.88% |
| 2018-03-31 | $1.36M | -95.80% |
| 2017-12-31 | $32.33M | 1254.21% |
| 2017-09-30 | $2.39M | -33.36% |
| 2017-06-30 | $3.58M | 32.52% |
| 2017-03-31 | $2.70M | 15.32% |
| 2016-12-31 | $2.34M | 51.32% |
| 2016-09-30 | $1.55M | 94.84% |
| 2016-06-30 | $795.00K | 67.02% |
| 2016-03-31 | $476.00K | 92.71% |
| 2015-12-31 | $247.00K | 100.00% |
| 2015-09-30 | - | - |
CRISPR Therapeutics generated $517.00K in revenue during Q2 2024, up 2.58% compared to the previous quarter, and up 0.52% compared to the same period a year ago.
CRISPR Therapeutics Revenue Breakdown
CRISPR Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Grant | $1.21M | $762.00K | - | - | - |
| Collaboration Revenue | $370.00M | $436.00K | - | - | - |
| Collaborative Arrangement Material Rights | - | - | $46.70M | $46.70M | $46.70M |
| Duchenne Muscular Dystrophy License | - | - | $151.10M | $151.10M | $151.10M |
| Myotonic Dystrophy Type One R And D Services | - | - | $1.10M | $1.10M | $1.10M |
| Specified Target Option Material Right | - | - | $11.80M | $11.80M | $11.80M |
| Exclusive License | - | - | $900.00M | - | - |
| Myotonic Dystrophy Type One License | - | - | $51.30M | $51.30M | $51.30M |
| Collaborative Arrangement Material Rights Fourth Exclusive License | - | - | $6.70M | - | - |
| Waiving Of Vertexs Material Right | - | - | - | - | $6.70M |
CRISPR Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Collaboration Revenue (99.68%), and Grant (0.32%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Jun 19 | Mar 19 | Dec 18 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Grant | $517.00K | $504.00K | - | - | - | - | - | $762.00K | $551.00K | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration Revenue | - | - | $200.00M | $70.00M | $100.00M | $6.00K | $94.00K | $158.00K | $178.00K | $12.35M | - | - | - | - | - | - | - | - | - | - |
| Myotonic Dystrophy Type One R And D Services | - | - | - | - | - | - | - | - | - | - | $1.10M | $1.10M | $1.10M | $1.10M | $1.10M | $1.10M | - | - | - | - |
| Collaborative Arrangement Material Rights | - | - | - | - | - | - | - | - | - | - | $46.70M | $46.70M | $46.70M | $46.70M | $46.70M | $46.70M | - | - | - | - |
| Duchenne Muscular Dystrophy License | - | - | - | - | - | - | - | - | - | - | $151.10M | $151.10M | $151.10M | $151.10M | $151.10M | $151.10M | - | - | - | - |
| Myotonic Dystrophy Type One License | - | - | - | - | - | - | - | - | - | - | $51.30M | $51.30M | $51.30M | $51.30M | $51.30M | $51.30M | - | - | - | - |
| Specified Target Option Material Right | - | - | - | - | - | - | - | - | - | - | $11.80M | $11.80M | $11.80M | $11.80M | $11.80M | $11.80M | - | - | - | - |
| License And Service | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $100.00K | $100.00K | $100.00K | $100.00K |
CRISPR Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Grant (100.00%).
CRISPR Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NVO | Novo Nordisk | $232.26B | $65.35B |
| REGN | Regeneron Pharmaceuticals | $13.12B | $3.55B |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| BEAM | Beam Therapeutics | $377.71M | $11.77M |
| CRSP | CRISPR Therapeutics | $370.00M | $517.00K |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| NTLA | Intellia Therapeutics | $36.27M | $6.96M |
| CRBU | Caribou Biosciences | $34.48M | $3.46M |
| VERV | Verve Therapeutics | $11.76M | $5.70M |
| EDIT | Editas Medicine | - | - |
| CWBR | CohBar | - | - |
| AVRO | AVROBIO | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
CRSP Revenue FAQ
What is CRISPR Therapeutics’s yearly revenue?
CRISPR Therapeutics's yearly revenue for 2023 was $370M, representing an increase of 84762.39% compared to 2022. The company's yearly revenue for 2022 was $436K, representing a decrease of -99.95% compared to 2021. CRSP's yearly revenue for 2021 was $913.08M, representing an increase of 168054.88% compared to 2020.
What is CRISPR Therapeutics’s quarterly revenue?
CRISPR Therapeutics's quarterly revenue for Q2 2024 was $517K, a 2.58% increase from the previous quarter (Q1 2024), and a -99.26% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $504K, a -99.75% decrease from the previous quarter (Q4 2023), and a -99.50% decrease year-over-year (Q1 2023). CRSP's quarterly revenue for Q4 2023 was $200M, a 100.00% increase from the previous quarter (Q3 2023), and a 3333233.33% increase year-over-year (Q4 2022).
What is CRISPR Therapeutics’s revenue growth rate?
CRISPR Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -59.48%, and for the last 5 years (2019-2023) was 27.77%.
What are CRISPR Therapeutics’s revenue streams?
CRISPR Therapeutics's revenue streams in c 23 are Grant, and Collaboration Revenue. Grant generated $1.21M in revenue, accounting 0.32% of the company's total revenue, up 58.27% year-over-year. Collaboration Revenue generated $370M in revenue, accounting 99.68% of the company's total revenue, up 84762.39% year-over-year.
What is CRISPR Therapeutics’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of CRISPR Therapeutics was Collaboration Revenue. This segment made a revenue of $370M, representing 99.68% of the company's total revenue.